Amphastar Pharmaceuticals, Inc. (AMPH)

Market Cap	1.84B
Revenue (ttm)	676.21M
Net Income (ttm)	154.69M
Shares Out	48.90M
EPS (ttm)	2.90
PE Ratio	12.96
Forward PE	9.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	590,179
Open	38.57
Previous Close	38.51
Day's Range	37.30 - 38.57
52-Week Range	37.30 - 67.66
Beta	0.82
Analysts	Buy
Price Target	66.00 (+75.63%)
Earnings Date	Aug 6, 2024

About AMPH

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection eme...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2014
• Employees: 1,761
• Stock Exchange: NASDAQ
• Ticker Symbol: AMPH

Financial Performance

In 2023, AMPH's revenue was $644.40 million, an increase of 29.14% compared to the previous year's $498.99 million. Earnings were $137.55 million, an increase of 50.51%.

Analyst Forecast

According to 5 analysts, the average rating for AMPH stock is "Buy." The 12-month stock price forecast is $66.0, which is an increase of 75.63% from the latest price.

Price Target

$66.0

(75.63% upside)

Analyst Consensus: Buy